GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Recordati SpA (OTCPK:RCDTF) » Definitions » Price-to-Owner-Earnings

Recordati SpA (Recordati SpA) Price-to-Owner-Earnings : 34.17 (As of May. 02, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Recordati SpA Price-to-Owner-Earnings?

As of today (2024-05-02), Recordati SpA's share price is $51.60. Recordati SpA's Owner Earnings per Share (TTM) ended in Dec. 2023 was $1.51. It's Price-to-Owner-Earnings for today is 34.17.


The historical rank and industry rank for Recordati SpA's Price-to-Owner-Earnings or its related term are showing as below:

RCDTF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 17.05   Med: 27.78   Max: 58.25
Current: 34.1

During the past 13 years, the highest Price-to-Owner-Earnings of Recordati SpA was 58.25. The lowest was 17.05. And the median was 27.78.


RCDTF's Price-to-Owner-Earnings is ranked worse than
60.57% of 421 companies
in the Drug Manufacturers industry
Industry Median: 28.45 vs RCDTF: 34.10

As of today (2024-05-02), Recordati SpA's share price is $51.60. Recordati SpA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.01. Therefore, Recordati SpA's PE Ratio for today is 25.72.

As of today (2024-05-02), Recordati SpA's share price is $51.60. Recordati SpA's EPS without NRI for the trailing twelve months (TTM) ended in was $2.01. Therefore, Recordati SpA's PE Ratio without NRI for today is 25.66.

During the past 13 years, Recordati SpA's highest PE Ratio without NRI was 32.34. The lowest was 12.36. And the median was 23.58.


Recordati SpA Price-to-Owner-Earnings Historical Data

The historical data trend for Recordati SpA's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recordati SpA Price-to-Owner-Earnings Chart

Recordati SpA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 38.85 34.43 31.67 26.75 33.82

Recordati SpA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.75 27.29 26.01 31.08 33.82

Competitive Comparison of Recordati SpA's Price-to-Owner-Earnings

For the Drug Manufacturers - General subindustry, Recordati SpA's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Recordati SpA's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Recordati SpA's Price-to-Owner-Earnings falls into.



Recordati SpA Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Recordati SpA's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=51.60/1.51
=34.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Recordati SpA  (OTCPK:RCDTF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Recordati SpA Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Recordati SpA's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Recordati SpA (Recordati SpA) Business Description

Traded in Other Exchanges
Address
Via Matteo Civitali 1, MIlan, ITA, 20148
Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth. The vast majority of the company's revenue is generated in Italy, followed by the United States, France, and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment, which includes the production of active ingredients.

Recordati SpA (Recordati SpA) Headlines

From GuruFocus

Recordati: Isturisa® (Osilodrostat) Approved In The U.S.

By PRNewswire PRNewswire 03-09-2020